Analysis of SIRT1 Expression in Plasma and in an In Vitro Model of Preeclampsia

Figure 1

(a) Plasma SIRT1 concentration from healthy (HP, ), gestational hypertensive (GH, ), and preeclamptic pregnant (PE, ) women. SIRT1 concentration found in plasma was reduced in PE vs. GH and HP controls (). (b) Intracellular SIRT1 concentration from HUVECs incubated with pools of healthy (HP, ), gestational hypertensive (GH, ), and preeclamptic pregnant (PE, ) women with plasma 10% (). SIRT1 concentration was reduced in HUVECs incubated with PE vs. HP and GH ( and , respectively). HUVECs with no plasma treatment were used as control (CT). Independent duplicates of each group were used to rule out any differences that could occur due to some characteristic of each cultivation, helping to consider the possible variables in cell culture procedure (1 is for the first experiment and 2 for the replicated experiment). The protein concentration used was 20 μg for all samples, and final values are mean, S.D. from samples 1 and 2 from each group. (c) SIRT1 plasmatic concentration from pregnant women who subsequently developed PE (case) compared to women who had healthy pregnancies (control). SIRT1 concentration was reduced in case vs. control women (). A comparison of concentration among groups was by the Kruskal-Wallis test followed by the Dunn multiple comparison test for the comparison between HP, GH, and PE. For the in vitro assay, we used one-way ANOVA followed by Tukey’s multiple comparison test. Nonparametric -tests were performed for comparisons between case and control groups (). For illustrative purposes, we chose to represent the analysis in the Tukey method for Box Whiskers; dots are 1.5 times the interquartile distance or to the highest or lowest point, whichever is shorter.

(a)

(b)

(c)